Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 07/24/26
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 07/20/26
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid TumorsAccesswire • 07/16/26
Moderna set for uneventful Q2 report ahead of key data readouts, says JefferiesProactive Investors • 07/14/26
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 07/13/26
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout24/7 Wall Street • 07/10/26
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026Accesswire • 07/09/26
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even MoreThe Motley Fool • 07/06/26
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.The Motley Fool • 07/03/26
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?Zacks Investment Research • 07/03/26
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?The Motley Fool • 07/03/26